Proton-P20 mg

Proton-P 20 mg Sodium is a proton pump inhibitor (PPI) indicated for all conditions where suppression of gastric acid secretion provides therapeutic benefit. It is available in oral (enteric-coated tablet) and intravenous (IV) formulations, allowing flexible use across outpatient and hospital settings.

Approved Indications

• Gastroesophageal Reflux Disease (GERD) — Relieves heartburn, regurgitation, and acid-related discomfort caused by stomach acid refluxing into the esophagus. Also indicated for the treatment and maintenance of erosive esophagitis associated with GERD.
• Peptic Ulcer Disease — Treats both benign gastric (stomach) ulcers and duodenal ulcers by reducing acid production, allowing the ulcer to heal.
• NSAID-Induced Ulcers — Prevents and treats gastric or duodenal ulcers caused by long-term use of non-steroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen, naproxen, and diclofenac.
• Eradication of Helicobacter pylori — Used in combination with antibiotics (e.g., amoxicillin and clarithromycin, or clarithromycin and metronidazole) to eradicate H. pylori infection, a key cause of recurrent peptic ulcers.
• Zollinger-Ellison Syndrome (ZES) — Manages pathological gastric hypersecretion in patients with ZES, a rare condition where gastrin-secreting tumors (gastrinomas) cause excessive acid production.
• Prevention of Acid Aspiration (IV) — Used perioperatively to prevent acid aspiration during anaesthesia (Mendelson's syndrome).
• Prevention of Rebleeding in Peptic Ulcer (IV) — High-dose IV Proton-P 20 mg is used post-endoscopy to prevent rebleeding from peptic ulcers.

Important: Proton-P 20 mg should be taken only as prescribed by a registered physician. Long-term use without medical supervision may mask symptoms of serious underlying conditions.

Mechanism of Action

Proton-P 20 mg is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production. After absorption and activation in the acidic environment of the gastric parietal cell canaliculi, Proton-P 20 mg covalently and irreversibly binds to the H⁺/K⁺-ATPase enzyme system (the proton pump) on the secretory surface of the gastric parietal cell.

This binding inhibits both basal (resting) and stimulated gastric acid secretion, regardless of the stimulus — whether histamine, gastrin, or acetylcholine. Because Proton-P 20 mg binds irreversibly to the proton pump, its acid-suppressing effect persists for longer than 24 hours, outlasting the drug's plasma half-life. Acid secretion does not resume until new proton pump molecules are synthesized by the parietal cell.

Proton-P 20 mg demonstrates a higher degree of selectivity for the proton pump at the pH levels found in the parietal cell canaliculi compared to other tissues, contributing to its favorable safety profile.

Pharmacokinetic Profile

Therapeutic Classification

Proton-P 20 mg belongs to the class of Proton Pump Inhibitors (PPIs). It is chemically a substituted benzimidazole and is classified among the most effective and widely used acid-suppressive agents in clinical medicine. Compared to first-generation PPIs (omeprazole), Proton-P 20 mg offers a more selective binding profile and fewer CYP2C19-dependent drug interactions.

Oral Tablets

• Take Proton-P 20 mg tablets approximately 30 minutes before a meal, preferably in the morning.
• Swallow the tablet whole with a glass of water. Do not split, crush, or chew the tablet — the enteric coating is essential to protect the drug from stomach acid and ensure proper release in the intestine.
• Food does not significantly affect overall absorption, but taking it before meals optimizes its acid-suppressing effect at meal times.
• If a dose is missed, take it as soon as remembered. If the next dose is due soon, skip the missed dose — do not double up.

IV Injection (Slow IV Bolus)

• For IV use only — not for intramuscular or subcutaneous administration.
• Reconstitute the lyophilized powder by adding 10 mL of 0.9% Sodium Chloride Injection to the vial. Swirl gently until dissolved.
• Administer as a slow IV injection over at least 2–5 minutes.
• Use only freshly prepared solution. The reconstituted solution may be stored at room temperature (up to 30°C) for a maximum of 4 hours.

IV Infusion

• Reconstitute with 10 mL of 0.9% Sodium Chloride Injection, then further dilute with one of the following to a final volume of 100 mL:
  • 0.9% Sodium Chloride Injection, or
  • 5% Dextrose Injection, or
  • Lactated Ringer's Injection
• Administer the infusion over approximately 15 minutes.
• The reconstituted vial solution may be stored at room temperature (up to 30°C) for a maximum of 4 hours before further dilution.
• The final admixed solution must be used within 24 hours from the time of initial reconstitution.
• Inspect visually for particulate matter and discoloration before administration. Discard if either is present.
• Do not mix Proton-P 20 mg IV with other medications in the same infusion bag or line.

Proton-P 20 mg has a relatively low potential for pharmacokinetic drug interactions compared to other PPIs. However, clinically significant interactions exist and should be carefully managed.

Clinically Significant Drug Interactions

Drugs with No Clinically Relevant Interaction

Based on clinical studies, Proton-P 20 mg does not significantly affect the pharmacokinetics of the following drugs and no dose adjustment is necessary: theophylline, diazepam, phenytoin, warfarin (kinetics — though pharmacodynamic monitoring required), metoprolol, nifedipine, carbamazepine, midazolam, clarithromycin, naproxen, piroxicam, oral contraceptives (levonorgestrel/ethinyl estradiol), digoxin, metronidazole, amoxicillin, and caffeine.

Drug–Food Interactions

Food does not clinically affect Proton-P 20 mg tablet absorption. However, the drug should ideally be taken 30 minutes before meals to maximize its effect at the time of peak acid stimulation.

Proton-P 20 mg is well tolerated in both short-term and long-term treatment. Most side effects are mild and transient. However, serious adverse effects may occur with prolonged or high-dose use.

Common Side Effects

Serious / Long-Term Side Effects

• Hypomagnesemia (low magnesium) — May occur with prolonged PPI use (generally >1 year). Can cause tetany, seizures, and cardiac arrhythmias. In some cases, PPI discontinuation was required as magnesium supplementation alone was insufficient. Monitor magnesium levels before and periodically during long-term therapy.
• Bone fractures — Published observational studies suggest PPI therapy (especially high-dose or >1 year duration) is associated with increased risk of osteoporosis-related hip, wrist, or spine fractures, particularly in elderly patients and those with kidney disease.
• Vitamin B12 deficiency (cyanocobalamin malabsorption) — Long-term PPI therapy may impair absorption of Vitamin B12 from food. This risk increases with duration of use. Monitoring may be warranted in long-term users.
• Clostridioides difficile-associated diarrhea (CDAD) — PPI therapy, including Proton-P 20 mg, may be associated with increased risk of C. difficile infection, particularly in hospitalized patients. Consider this diagnosis in patients with persistent, unexplained diarrhea.
• Severe skin reactions — Rare but serious events including erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis, and DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms) have been reported.
• Acute interstitial nephritis — Rare but reported with PPI use. Discontinue Proton-P 20 mg if suspected.
• Thrombophlebitis (IV) — Infusion site reactions including thrombophlebitis have been associated with IV Proton-P 20 mg. Monitor the infusion site regularly.
• Zinc deficiency (IV formulation) — IV Proton-P 20 mg contains EDTA, a chelating agent for zinc. Zinc supplementation should be considered in patients predisposed to zinc deficiency.
• Fundic gland polyps — Associated with long-term PPI use, particularly beyond 1 year. Generally benign and reversible upon discontinuation.

Use During Pregnancy

Proton-P 20 mg is classified as FDA Pregnancy Category B. Animal reproductive studies have not demonstrated a risk to the fetus; however, there are no adequate and well-controlled studies in pregnant women. Animal reproduction studies are not always predictive of human response.

Proton-P 20 mg should be used during pregnancy only if clearly needed — when the potential benefit to the mother justifies the potential risk to the fetus. Pregnant women experiencing acid-related symptoms should discuss the risks and benefits with their healthcare provider before use. Lifestyle modifications and antacids may be considered as first-line approaches where possible.

Use During Breastfeeding

Proton-P 20 mg and its metabolites are excreted in human breast milk. The potential effect on a nursing infant is unknown. Since Proton-P 20 mg has demonstrated carcinogenic potential in long-term animal studies, a decision must be made whether to:

• Discontinue breastfeeding, or
• Discontinue Proton-P 20 mg therapy

This decision should be made in consultation with the healthcare provider, taking into account the importance of the drug to the mother and the potential risk to the infant. Breastfeeding women who require PPI therapy should seek medical guidance before proceeding.

Tablet Handling

Proton-P 20 mg enteric-coated tablets must not be split, crushed, or chewed. The enteric coating is critical to prevent premature degradation in stomach acid and ensure proper drug delivery in the small intestine where absorption occurs. Crushing the tablet destroys the enteric coat and significantly reduces efficacy.

Masking of Serious Gastric Conditions

Symptomatic response to Proton-P 20 mg does not rule out the presence of gastric malignancy, including gastric cancer. In patients with persistent symptoms, unexplained weight loss, early satiety, or dysphagia, further diagnostic investigation (including endoscopy) should be performed before or during treatment. Do not use Proton-P 20 mg as a long-term empirical therapy without appropriate investigation.

Long-Term Use: Vitamin B12 Deficiency

Prolonged use of Proton-P 20 mg (generally >3 years) may lead to malabsorption of cyanocobalamin (Vitamin B12), as adequate gastric acid is required for B12 release from food. This can result in B12 deficiency, particularly in patients with poor dietary intake or existing risk factors. Periodic monitoring of B12 levels is advisable in long-term users.

Long-Term Use: Bone Health

Long-term (especially >1 year) and high-dose PPI therapy may be associated with increased risk of osteoporosis-related fractures of the hip, wrist, and spine. Patients on long-term therapy — especially elderly patients, postmenopausal women, and those with pre-existing osteoporosis — should discuss bone health management with their physician. Adequate calcium and Vitamin D intake and bone density monitoring may be warranted.

Hypomagnesemia Monitoring

Consider measuring serum magnesium levels before initiating PPI therapy and periodically thereafter, especially in patients expected to be on Proton-P 20 mg long-term or in those already taking medications known to cause hypomagnesemia (e.g., digoxin or diuretics). Hypomagnesemia can present as muscle spasms, tremors, palpitations, or seizures.

C. difficile-Associated Diarrhea

PPI therapy including Proton-P 20 mg has been associated with increased risk of Clostridioides difficile-associated diarrhea (CDAD). Evaluate any patient on Proton-P 20 mg who develops persistent diarrhea for CDAD. If confirmed, discontinue Proton-P 20 mg and initiate appropriate treatment.

IV-Specific Precautions

• Proton-P 20 mg IV contains EDTA (edetate disodium), a chelating agent that may worsen zinc deficiency. Zinc supplementation should be considered in at-risk patients (malnutrition, post-surgery, burns).
• Monitor IV infusion sites for signs of thrombophlebitis. Remove catheter and rotate site if local inflammation occurs.
• Switch to oral therapy as soon as the patient is able to swallow.

Use in Patients with Hepatic Impairment

Proton-P 20 mg is extensively metabolized by the liver. In patients with severe hepatic impairment, the maximum recommended dose is 20 mg once daily due to reduced metabolic clearance and the potential for drug accumulation. Monitor liver function tests in patients with hepatic disease on long-term therapy.

False-Positive Urine Tests

Proton-P 20 mg may cause false-positive results in urine screening tests for tetrahydrocannabinol (THC). Positive results should be confirmed by a more specific analytical method such as gas chromatography/mass spectrometry (GC-MS).

Known Toxicity Profile

There are no known symptoms of overdosage in humans from Proton-P 20 mg alone at available clinical doses. Proton-P 20 mg has a wide therapeutic margin and exhibits a low acute toxicity profile. However, reports of overdose exist, particularly in the context of intentional ingestion.

In cases of very high doses or intentional overdose, the following general symptoms may theoretically occur, consistent with other PPIs:

• Nausea, vomiting, abdominal discomfort
• Headache, dizziness
• Confusion or drowsiness (at very high doses)

Management of Overdose

• There is no specific antidote for Proton-P 20 mg overdose.
• Management is symptomatic and supportive. Vital signs should be monitored and general supportive measures initiated as required.
• Since Proton-P 20 mg is highly protein-bound (~98%), it is not readily dialyzable — hemodialysis is not expected to be effective in enhancing elimination.
• Gastric emptying (emesis or gastric lavage) may be considered if presentation is early and large ingestion is suspected, with appropriate airway protection.
• Seek emergency medical care. Contact your national Poison Control Center for guidance.

• Store in a cool, dry place, away from direct sunlight, heat, and moisture.
• Keep below 30°C. Do not refrigerate or freeze oral tablets unless directed by the manufacturer.
• Store in the original packaging to protect from light and humidity.
• Keep out of reach of children and pets.
• Do not use after the expiry date printed on the packaging.
• The reconstituted IV solution should be stored at room temperature (≤30°C) and used within the stability windows described in the Reconstitution section.
• Return unused or expired Proton-P 20 mg to a pharmacy for safe disposal — do not discard via household waste or wastewater.

Pediatric Patients

Proton-P 20 mg is approved for use in children as young as 5 years of age for the short-term treatment of erosive esophagitis associated with GERD. Safety and efficacy in children below 5 years have not been established for most indications. Weight-based dosing is used in pediatric patients:

• 15 kg to <40 kg: 20 mg once daily for up to 8 weeks
• ≥40 kg: 40 mg once daily for up to 8 weeks

For pediatric patients who are known CYP2C19 poor metabolizers, dose reduction should be considered due to significantly higher drug exposure.

Elderly Patients (≥65 years)

No overall differences in safety or efficacy have been observed between elderly and younger patients. In clinical trials, the pharmacokinetics of Proton-P 20 mg in elderly patients (65–76 years) were similar to younger subjects after IV administration. No routine dose adjustment is required in elderly patients, except in patients with Zollinger-Ellison Syndrome where the maximum oral dose in the elderly is 40 mg/day.

Elderly patients on long-term PPI therapy should be monitored for fracture risk, Vitamin B12 deficiency, and hypomagnesemia, as they are at higher baseline risk for these complications.

Patients with Hepatic Impairment

Proton-P 20 mg AUC is significantly increased in patients with severe hepatic impairment (Child-Pugh Class C). The recommended maximum dose is 20 mg once daily. Liver function tests should be monitored during long-term use in these patients. Mild to moderate hepatic impairment typically does not require dose adjustment.

Patients with Renal Impairment

No dose adjustment is required in patients with renal impairment, including those on hemodialysis. Since Proton-P 20 mg is highly protein bound, it is not readily dialyzable.

CYP2C19 Poor Metabolizers

Approximately 3% of the Caucasian population and 15–20% of Asian populations are CYP2C19 poor metabolizers. In these individuals, Proton-P 20 mg AUC may be significantly higher than in extensive metabolizers. In pediatric patients who are known poor metabolizers, a dose reduction should be considered to avoid excessive drug exposure.

Proton-P 20 mg IV is available as a lyophilized (freeze-dried) powder in a single-dose vial (40 mg). It must be reconstituted before administration. Use aseptic technique throughout preparation.

For IV Injection (Slow Bolus)

For IV Infusion

Important: Do not mix Proton-P 20 mg IV with other medications in the same syringe or infusion bag. Inspect the reconstituted and diluted solution for particulate matter or discoloration before use — discard if either is present.